Acute myocarditis associated with anti-COVID-19 vaccination

Nevet, Alon

doi:10.7774/cevr.2021.10.2.196

Cited by 28 publications

(19 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subsequently, 10 studies were excluded for the following reasons: inclusion of pediatric cases (n=7) [20] , [21] , [22] , [23] , [24] , [25] , [26] , diagnosis of multisystem inflammatory syndrome (n=1) [27] , analysis of incidence data of a pharmacovigilance database (n=1) [28] and opinion paper (n=1) [29] . Therefore, 39 studies were included; 37 of them [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [52] , [53] , [54] , [55] , [56] , [57] , [58] , [59] , [60] , [61] , [62] , [63] , [64] , [65] , [66] provided individual data of 86 participants, forming the pooled cohort. On the other hand, 2 observational studies [67] , [68] reported aggregated data of 43 patients.…”

Section: Resultsmentioning

confidence: 99%

Myocarditis following mRNA Covid-19 vaccination: A pooled analysis

Bellos

Karageorgiou

Viskin

2022

Vaccine

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Myocarditis following mRNA Covid-19 vaccination: A pooled analysis

Bellos

Karageorgiou

Viskin

2022

Vaccine

View full text Add to dashboard Cite

“…After the start of the vaccination campaign in Israel, its Ministry of Health started active surveillance of myocarditis in February 2021 following early reports on the occurrence of myocarditis as a possible adverse side effect [ 6 ]. The first case series in the literature appeared three months later and described three young male patients who had been diagnosed with myocarditis two days after the second dose of the Pfizer-BioNTech vaccine [ 25 ].…”

Section: Myocarditis Pericarditis and Covid-19 Vaccinesmentioning

confidence: 99%

The benefit of vaccination against COVID-19 outweighs the potential risk of myocarditis and pericarditis

2022

View full text Add to dashboard Cite

Vaccines against coronavirus 2019 disease (COVID-19) have shown to be greatly effective in preventing viral spread, serious illness and death from this infectious disease and are therefore critical for the management of the COVID-19 pandemic. However, the listing of myocarditis and pericarditis as possible rare side effects of the messenger RNA (mRNA) vaccines against COVID-19 by regulatory agencies has sparked discussion on the vaccines’ safety. The most important published cohort studies to date demonstrat that myocarditis is a very rare side effect after COVID-19 mRNA vaccination, with an incidence of approximately 1–4 cases per 100,000 vaccinated persons. Young males (16–29 years) appear to be at highest risk, predominantly after receiving the second dose. The disease course is self-limiting in a vast majority of cases: 95% of patients show a rapid resolution of symptoms and normalisation of cardiac biomarkers, electro- and echocardiographic findings within days. Importantly, the available data suggest that the incidence rate of myocarditis in the context of COVID-19 is much greater than the risk of this side effect following vaccination. We conclude that the benefit of vaccination against COVID-19 outweighs the potential risk of myocarditis and pericarditis in both adolescents and adults. Prospective follow-up of patients who have developed these complications after vaccination is required to assess long-term outcomes.

show abstract

“…The number of hospitalizations regarding nerve palsy also falls out of trend from the last 5-year data further adding fuel to the suspicion. Nevet from Israel has reported three cases of potentially life-threatening acute myocarditis within 2 days of the second dose [ 191 ]. On 9 July 2021, European medicines agency (EMA) enlisted myocarditis and pericarditis as side effects of BNT162b2 [ 192 ].…”

Section: Vaccines Approved For Public Usementioning

confidence: 99%

Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges

et al. 2021

View full text Add to dashboard Cite

The emergence of a novel coronavirus viz., severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in late 2019 and its subsequent substantial spread produced the coronavirus disease 2019 (COVID-19) pandemic worldwide. Given its unprecedented infectivity and pathogenicity, the COVID-19 pandemic had a devastating impact on human health, and its clinical management has been a great challenge, which has led to the development and speedy trials of several vaccine candidates against SARS-CoV-2 at an exceptional pace. As a result, several COVID-19 vaccines were made commercially available in the first half of 2021. Although several COVID-19 vaccines showed promising results, crucial insights into their epidemiology, protective mechanisms, and the propensities of reinfection are not largely reviewed. In the present report, we provided insights into the prospects of vaccination against COVID-19 and assessed diverse vaccination strategies including DNA, mRNA, protein subunits, vector-based, live attenuated, and inactivated whole/viral particle-based vaccines. Next, we reviewed major aspects of various available vaccines approved by the World Health Organization and by the local administrations to use against COVID-19. Moreover, we comprehensively assessed the success of these approved vaccines and also their untoward effects, including the possibility of reinfection. We also provided an update on the vaccines that are under development and could be promising candidates in the future. Conclusively, we provided insights into the COVID-19 vaccine epidemiology, their potency, and propensity for SARS-CoV-2 reinfection, while a careful review of their current status, strategies, success, and future challenges was also presented.

show abstract

Acute myocarditis associated with anti-COVID-19 vaccination

Cited by 28 publications

References 2 publications

Myocarditis following mRNA Covid-19 vaccination: A pooled analysis

Myocarditis following mRNA Covid-19 vaccination: A pooled analysis

The benefit of vaccination against COVID-19 outweighs the potential risk of myocarditis and pericarditis

Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges

Contact Info

Product

Resources

About